DFTX vs DYN: fair value comparison
Definium Therapeutics, Inc. and Dyne Therapeutics, Inc. · Updated 2026-10-19
DFTX has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. DYN has no fair-value estimate yet: no usable analyst consensus or too few reported quarters. Within Healthcare, DFTX currently ranks higher by quality score.
| DFTX | DYN | |
|---|---|---|
| Verdict | No estimate yet | No estimate yet |
| Last price | $32.10 | $14.25 |
| 12-month range | $10.68–$48.45 | $14.25–$26.78 |
| Rank by discount to fair value | — | — |
| Rank by quality score | #234 of 301 Healthcare | #236 of 301 Healthcare |
| Quality grade | F | F |
| Leverage | Low | Low |
| Margin trend | — | Expanding |
| RSI zone | Neutral | Oversold |
| 50/200-day trend | Mixed | Mixed |
| 52-week position | The upper-middle quarter | The bottom quarter |
Full single-stock breakdowns: DFTX fair value analysis · DYN fair value analysis